Drug intelligence / Profile preview

ALC-0315

Development stage: Unknown
Lead developer: Acuitas Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular, Intravenous

Overview

ALC-0315 is an ionizable cationic lipid that serves as a critical component of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. It is most notably used as one of the four lipids in the BNT162b2 (Comirnaty) mRNA vaccine developed by Pfizer and BioNTech. The lipid is designed to be neutral at physiological pH but becomes positively charged in the acidic environment of the endosome, facilitating the encapsulation of negatively charged mRNA and subsequent endosomal escape for cytoplasmic delivery. In research settings, it is frequently used as a benchmark for evaluating the efficiency and safety of novel LNP formulations.

Other names: [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate)

Beyond the preview

Go deeper on ALC-0315.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALC-0315.

Explore the full profile